These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 11017842

  • 1. Vancomycin-induced neutropenia resolves after substitution with teicoplanin.
    Sanche SE, Dust WN, Shevchuk YM.
    Clin Infect Dis; 2000 Sep; 31(3):824-5. PubMed ID: 11017842
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin.
    Hsiao SH, Chang CM, Tsai JC, Lin CY, Liao LH, Lin WL, Wu TJ.
    Ann Pharmacother; 2007 May; 41(5):891-4. PubMed ID: 17426073
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH, Hsu RB.
    Scand J Infect Dis; 2008 May; 40(6-7):462-7. PubMed ID: 18584532
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.
    Mergenhagen KA, Pasko MT.
    Ann Pharmacother; 2007 Sep; 41(9):1531-5. PubMed ID: 17652126
    [Abstract] [Full Text] [Related]

  • 9. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L, Encinas MP, Morín LS, Vilches P, Gutiérrez N, García-Sanz R, Caballero D, Hurlé AD.
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [Abstract] [Full Text] [Related]

  • 10. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
    Hahn-Ast C, Glasmacher A, Arns A, Mühling A, Orlopp K, Marklein G, Von Lilienfeld-Toal M.
    Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin.
    Marshall C, Street A, Galbraith K.
    J Infect; 1998 Jul; 37(1):82-3. PubMed ID: 9733391
    [Abstract] [Full Text] [Related]

  • 13. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
    Sidi V, Roilides E, Bibashi E, Gompakis N, Tsakiri A, Koliouskas D.
    J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Adequate intrathecal diffusion of teicoplanin after failure of vancomycin, administered in continuous infusion in three cases of shunt associated meningitis].
    Jourdan C, Convert J, Peloux A, Boussaid O, Grando J, Tigaud S.
    Pathol Biol (Paris); 1996 May; 44(5):389-92. PubMed ID: 8758482
    [Abstract] [Full Text] [Related]

  • 19. Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases.
    Arda B, Yamazhan T, Sipahi OR, Islekel S, Buke C, Ulusoy S.
    Int J Antimicrob Agents; 2005 May; 25(5):414-8. PubMed ID: 15848297
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.